A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Registration Number
NCT04442022
Lead Sponsor
Karyopharm Therapeutics Inc
Brief Summary

The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. This study consists of 3 arms each in Phase 2 and 3. Phase 2 portion of the study...

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
501
Inclusion Criteria

  • Have pathologically confirmed de novo DLBCL or DLBCL transformed from previously diagnosed indolent lymphoma (e.g., follicular lymphoma). Patient with high-grade lymphoma with c-MYC, Bcl2 and/or Bcl6 rearrangements are eligible (only for Phase 2). (Documentation to be provided).

  • Have received at least 1 but no more than 3 prior lines of systemic therapy for the treatment of DLBCL with relapsed or refractory disease following their most recent regimen.

    • Salvage chemoimmunotherapy followed by stem cell transplantation will be considered as 1 line of systemic therapy.
    • Maintenance therapy will not be counted as a separate line of systemic therapy.
    • Radiation with curative intent for localized DLBCL will not be counted as 1 line of systemic therapy.

  • Positron emission tomography (PET) positive measurable disease with at least 1 node having the longest diameter (LDi) greater than (>) 1.5 centimeter (cm) or 1 extranodal lesion with LDi >1 cm (per the Lugano Criteria 2014). The Deauville 5-point scale (D5PS) score assessed on the FDG PET/CT should be between 3 to 5.

  • Not intended for HSCT or CAR-T cell therapy based on objective clinical criteria determined by the treating physician. Patients who cannot receive HSCT due to active disease are allowed on study (up to approximately 15 percent [%] of patients enrolled in each Phase). Documentation on lack of intention to proceed to receive HSCT or CAR-T therapy must be provided by the treating physician.

  • Adequate bone marrow function at screening, defined as:

    • Absolute neutrophil count (ANC) ≥1*10^9 per liter (/L).
    • Platelet count ≥100*10^9/L (without platelet transfusion less than [<] 14 days prior to Cycle 1 Day 1 [C1D1]).
    • Hemoglobin ≥8.5 gram per deciliter (g/dL) (without red blood cell transfusion <14 days prior to C1D1).

  • Circulating lymphocytes less than or equal to (≤) 50*10^9/L.

  • Adequate liver and kidney function, defined as:

    • Aspartate transaminase (AST) or alanine transaminase (ALT) ≤2.5*upper limit of normal (ULN), or ≤5*ULN in cases with known lymphoma involvement in the liver.
    • Serum total bilirubin ≤2*ULN, or ≤5*ULN if due to Gilbert syndrome or in cases with known lymphoma involvement in the liver.
    • Calculated creatinine clearance (CrCl) ≥30 milliliter per minute (mL/min) based on Cockcroft-Gault formula.

  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.

  • An estimated life expectancy of >3 months at Screening.

  • Patients with primary refractory DLBCL defined as no response or relapse within 6 months after ending first-line treatment, will be allowed in the study.

  • Agree to highly effective contraception during the duration of the study with contraception use continuing for 12 months after the last dose of study treatment

  • Female patients of childbearing potential must have a negative serum pregnancy test at Screening and agree to use highly effective methods of contraception throughout the study and for 12 months following the last dose of study treatment (except patients with Non-Childbearing potential: Age >50 years and naturally amenorrhoeic for >1 year, or previous bilateral salpingo-oophorectomy, or hysterectomy).

  • Male patients who are sexually active must use highly effective methods of contraception throughout the study and for 12 months following the last dose of study treatment. Male patients must agree not to donate sperm during the study treatment period and for 12 months following the last dose of study treatment.

Read More
Exclusion Criteria

  • DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma, composite lymphoma (Hodgkin's lymphoma + non-Hodgkin's lymphoma [NHL]), DLBCL transformed from diseases other than indolent NHL; primary mediastinal (thymic) large B-cell lymphoma (PMBL); T-cell rich large B-cell lymphoma.

  • Previous treatment with selinexor or other XPO1 inhibitors.

  • Contraindication to any drug contained in the combination therapy regimen (SR-GDP).

  • Known active central nervous system or meningeal involvement by DLBCL at time of Screening.

  • Use of any standard or experimental anti-DLBCL therapy (including nonpalliative radiation, chemotherapy, immunotherapy, radio-immunotherapy, or any other anticancer therapy) <21 days prior to C1D1 (prednisone <30 mg or equivalent is permitted; palliative radiation is permitted only if on non-target lesions).

  • Any AE, by C1D1, which has not recovered to Grade ≤1 (Common Terminology Criteria for Adverse Events [CTCAE], v.5.0), or returned to baseline, related to the previous DLBCL therapy, except hematological abnormalities (as specified in the inclusion criteria) and alopecia.

  • Major surgery <14 days of Cycle 1 Day 1.

  • Hematopoietic stem cell transplantation/CAR-T therapy as follows:

    • Autologous stem cell transplant (SCT) <100 days or allogeneic-SCT <180 days prior to C1D1
    • Active graft-versus-host disease (GVHD) after allogeneic SCT (or cannot discontinue GVHD treatment or prophylaxis)
    • CAR-T cell infusion <90 days prior to Cycle 1

  • Neuropathy Grade ≥2 (CTCAE, v.5.0).

  • Any life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the patient's safety, or being compliant with the study procedures.

  • Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within 7 days prior to first dose of study treatment; however, prophylactic use of these agents is acceptable (including parenteral).

  • Patient with active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infections:

    • Patient with active HBV are allowed if antiviral therapy for hepatitis B has been given for >8 weeks and viral load is <100 International units (IU)/mL prior to first dose of study treatment.
    • Patients with known history of HCV or found to be HCV antibody positive on screening, are allowed if there is documentation of negative viral load per institutional standard.
    • Patients with HIV are allowed if they have a negative viral load per institutional standard, and no history of acquired immune deficiency syndrome (AIDS)-defining opportunistic infections in the last year.

  • Inability to swallow tablets, malabsorption syndrome, or any other gastrointestinal (GI) disease or dysfunction that could interfere with absorption of study treatment.

  • Breastfeeding or pregnant women.

  • Inability or unwillingness to sign an informed consent form (ICF).

  • In the opinion of the Investigator, patient who are significantly below their ideal body weight.

  • Patients who received a live attenuated vaccine within prior 28 days of the first dose of study treatment.

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Phase 2: Selinexor 40 mg + R-GDPRituximab (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor 40 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally once weekly (QW) for each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
Phase 2: Selinexor 40 mg + R-GDPSelinexor (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor 40 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally once weekly (QW) for each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
Phase 2: Selinexor 40 mg + R-GDPGemcitabine (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor 40 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally once weekly (QW) for each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
Phase 2: Selinexor 40 mg + R-GDPDexamethasone (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor 40 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally once weekly (QW) for each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
Phase 2: Selinexor 40 mg + R-GDPCisplatin (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor 40 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally once weekly (QW) for each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
Phase 2: Selinexor 40 mg + R-GDPSelinexor (continuous therapy)Patients with RR DLBCL will receive combination therapy of selinexor 40 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally once weekly (QW) for each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
Phase 2: Selinexor 60 mg + R-GDPSelinexor (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor 60 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 2: Selinexor 60 mg + R-GDPRituximab (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor 60 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 2: Selinexor 60 mg + R-GDPGemcitabine (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor 60 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 2: Selinexor 60 mg + R-GDPDexamethasone (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor 60 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 2: Selinexor 60 mg + R-GDPCisplatin (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor 60 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 2: Selinexor 60 mg + R-GDPSelinexor (continuous therapy)Patients with RR DLBCL will receive combination therapy of selinexor 60 mg orally at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by single-agent continuous therapy with selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 2: R-GDPRituximab (combination therapy)Patients with RR DLBCL will receive R-GDP on specified days (Days 1, 2, 3, 4, and 8) for each 21-day cycle for up to 6 cycles.
Phase 2: R-GDPGemcitabine (combination therapy)Patients with RR DLBCL will receive R-GDP on specified days (Days 1, 2, 3, 4, and 8) for each 21-day cycle for up to 6 cycles.
Phase 2: R-GDPDexamethasone (combination therapy)Patients with RR DLBCL will receive R-GDP on specified days (Days 1, 2, 3, 4, and 8) for each 21-day cycle for up to 6 cycles.
Phase 2: R-GDPCisplatin (combination therapy)Patients with RR DLBCL will receive R-GDP on specified days (Days 1, 2, 3, 4, and 8) for each 21-day cycle for up to 6 cycles.
Phase 3: Selinexor (Selected Dose) + R-GDP followed by Selinexor 60 mgSelinexor (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Selinexor (Selected Dose) + R-GDP followed by Selinexor 60 mgGemcitabine (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Selinexor (Selected Dose) + R-GDP followed by Selinexor 60 mgDexamethasone (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Selinexor (Selected Dose) + R-GDP followed by Selinexor 60 mgCisplatin (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Selinexor (Selected Dose) + R-GDP followed by Selinexor 60 mgSelinexor (continuous therapy)Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Selinexor (Selected Dose) + R-GDP followed by Selinexor 60 mgRituximab (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by selinexor 60 mg orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Selinexor (Selected Dose) + R-GDP followed by PlaceboSelinexor (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Selinexor (Selected Dose) + R-GDP followed by PlaceboRituximab (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Selinexor (Selected Dose) + R-GDP followed by PlaceboGemcitabine (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Selinexor (Selected Dose) + R-GDP followed by PlaceboDexamethasone (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Selinexor (Selected Dose) + R-GDP followed by PlaceboCisplatin (combination therapy)Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Selinexor (Selected Dose) + R-GDP followed by PlaceboPlacebo matching for Selinexor (continuous therapy)Patients with RR DLBCL will receive combination therapy of selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Placebo + R-GDP followed by PlaceboPlacebo matching for Selinexor (combination therapy)Patients with RR DLBCL will receive combination therapy of placebo matching for selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Placebo + R-GDP followed by PlaceboRituximab (combination therapy)Patients with RR DLBCL will receive combination therapy of placebo matching for selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Placebo + R-GDP followed by PlaceboGemcitabine (combination therapy)Patients with RR DLBCL will receive combination therapy of placebo matching for selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Placebo + R-GDP followed by PlaceboDexamethasone (combination therapy)Patients with RR DLBCL will receive combination therapy of placebo matching for selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Placebo + R-GDP followed by PlaceboCisplatin (combination therapy)Patients with RR DLBCL will receive combination therapy of placebo matching for selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
Phase 3: Placebo + R-GDP followed by PlaceboPlacebo matching for Selinexor (continuous therapy)Patients with RR DLBCL will receive combination therapy of placebo matching for selinexor (selected dose from Phase 2) at Day 1 and Day 8 of each 21-day cycle for up to 6 cycles in combination with R-GDP followed by matching placebo for selinexor orally QW for each 28-day cycle until PD or unacceptable toxicity.
Primary Outcome Measures
NameTimeMethod
Phase 3: Progression-free Survival (PFS): Based on Lugano Criteria 2014From date of initial randomization to the date of disease progression or death (maximum of 5 years from randomization)
Phase 2: Overall Response Rate (ORR): Based on Lugano Criteria 2014From date of initial randomization to the date of disease progression or initiating a new DLBCL treatment (maximum of 5 years from randomization)
Secondary Outcome Measures
NameTimeMethod
Phase 3: Overall Response Rate: Based on Lugano Criteria 2014From date of initial randomization to the date of disease progression or initiating a new DLBCL treatment (maximum of 5 years from randomization)
Phase 3: Number of Patients with Adverse EventsUp to 30 days after last dose of study drug (maximum of 5 years from randomization)
Phase 2: Progression-free Survival: Based on Lugano Criteria 2014From date of initial randomization to the date of disease progression or death (maximum of 5 years from randomization)
Phase 2: Overall Survival (OS)From date of initial randomization until death (maximum of 5 years from randomization)
Phase 3: Overall SurvivalFrom date of initial randomization until death (maximum of 5 years from randomization)
Phase 2: Overall Response Rate at the End of Combination Therapy (ORR-EoC): Based on Lugano Criteria 2014From C1D1 (Cycles 1 up to 6; 21 days per cycle) up to 28 days after EoC therapy
Phase 2: Overall Response Rate at the End of Combination Therapy: Based on Modified Lugano CriteriaFrom C1D1 (Cycles 1 up to 6; 21 days per cycle) up to 28 days after EoC therapy
Phase 2: Duration of Response (DOR): Based on Lugano Criteria 2014From time of first response until disease progression or death (maximum of 5 years from randomization)
Phase 2: Number of Patients with Adverse Events (AEs)Up to 30 days after last dose of study drug (maximum of 5 years from randomization)
Phase 3: Overall Response Rate at the End of Combination Therapy: Based on Lugano Criteria 2014From C1D1 (Cycles 1 up to 6; 21 days per cycle) up to 28 days after EoC therapy
Phase 3: Overall Response Rate at the End of Combination Therapy: Based on Modified Lugano CriteriaFrom C1D1 (Cycles 1 up to 6; 21 days per cycle) up to 28 days after EoC therapy
Phase 3: Progression-free Survival: Based on Modified Lugano CriteriaFrom date of initial randomization to the date of disease progression or death (maximum of 5 years from randomization)
Phase 3: Duration of Response: Based on Lugano Criteria 2014From time of first response until disease progression or death (maximum of 5 years from randomization)

Trial Locations

Locations (57)

Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers

🇺🇸

Chandler, Arizona, United States

Arizona Oncology Associates

🇺🇸

Tucson, Arizona, United States

The Oncology Institute (TOI) Clinical Research

🇺🇸

Cerritos, California, United States

Investigative Clinical Research of Indiana, LLC

🇺🇸

Indianapolis, Indiana, United States

Norton Cancer Institute, St. Matthews

🇺🇸

Louisville, Kentucky, United States

Tulane Cancer Center

🇺🇸

New Orleans, Louisiana, United States

University of Maryland Greenebaum Comprehensive Cancer Center

🇺🇸

Baltimore, Maryland, United States

Comprehensive Cancer Centers of Nevada - Town Center

🇺🇸

Las Vegas, Nevada, United States

New Mexico Cancer Care Alliance

🇺🇸

Albuquerque, New Mexico, United States

Stony Brook

🇺🇸

Stony Brook, New York, United States

Gabrail Cancer Center Research LLC

🇺🇸

Canton, Ohio, United States

Texas Oncology - Medical City Dallas

🇺🇸

Dallas, Texas, United States

Texas Oncology - Presbyterian Dallas Cancer Center

🇺🇸

Dallas, Texas, United States

Texas Oncology - Sammons

🇺🇸

Dallas, Texas, United States

Texas Oncology - Fort Worth

🇺🇸

Fort Worth, Texas, United States

Texas Oncology - Plano East

🇺🇸

Plano, Texas, United States

Texas Oncology - Tyler

🇺🇸

Tyler, Texas, United States

The University of Texas Health Science Center at Tyler DBA UT Health East Texas HOPE Cancer Center

🇺🇸

Tyler, Texas, United States

Providence Regional Cancer Partnership

🇺🇸

Everett, Washington, United States

Kepler Universitaetskrankenhaus Med Campu III - Onkologie

🇦🇹

Linz, Austria

University of Vienna, Medical Clinic I, Hematology

🇦🇹

Vienna, Austria

Hospital Hietzing

🇦🇹

Vienna, Austria

Jiangsu Province Hospital

🇨🇳

Nanjing, Jiangsu, China

The First Affiliated Hospital of Soochow University

🇨🇳

Suzhou, Jiangsu, China

Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School

🇨🇳

Huangpu, Shanghai, China

Zhongshan Hospital Fudan University

🇨🇳

Xuhui District, Shanghai, China

Huaxi Hospital Sichuan University

🇨🇳

Chengdu, Sichuan, China

The first affiliated Hospital, Zhejiang University

🇨🇳

Hangzhou, Zhejiang, China

Assuta Ashdod Medical Center

🇮🇱

Ashdod, Israel

Soroka Medical Center

🇮🇱

Beer Sheva, Israel

Rambam health care campus (Department of Hematology & Bone Marrow Transplantation)

🇮🇱

Haifa, Israel

Wolfson Medical Center

🇮🇱

Holon, Israel

Hadassah Medical Center

🇮🇱

Jerusalem, Israel

Rabin Medical Center

🇮🇱

Petach Tikva, Israel

Assuta medical centers - Ramat Hachayal

🇮🇱

Tel aviv, Israel

Sourasky Medical Center

🇮🇱

Tel Aviv, Israel

National Cancer Institute

🇮🇹

Naples, Napoli, Italy

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello

🇮🇹

Palermo, Sicilia, Italy

AOU City of Health and Science of Turin

🇮🇹

Turin, Torino, Italy

AOU Ospedali Riuniti-Università Politecnica delle Marche Clinica di Ematologia

🇮🇹

Ancona, Italy

AOU Policlinico S.Orsola Malpighi di Bologna, University of Bologna

🇮🇹

Bologna, Italy

UOC Ematologia ad Indirizzo Oncologico, AORN "Sant'Anna e San Sebastiano"

🇮🇹

Caserta, Italy

AOU Maggiore della Carità SCDU Ematologia

🇮🇹

Novara, Italy

DIP. Oncologia- Ematologia, UOSD Centro Diagnosie TerapiaDei Linfomi

🇮🇹

Pescara, Italy

Fondatione Policlinico Universitario A. Gemelli

🇮🇹

Rome, Italy

Pratia MCM Krakow

🇵🇱

Krakow, Lesser, Poland

Szpitale pomorskie gdynia dept of haematology

🇵🇱

Gdynia, Pomerania, Poland

Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku Uniwersytecki Szpital Kliniczny im. Jana Mikulicza - Radeckiego we Wrocławiu

🇵🇱

Wroclaw, Radeckiego, Poland

CM Pratia Poznań

🇵🇱

Skorzewo, Wielkopolska, Poland

Institute of Hematology and Transfusion Medicine

🇵🇱

Warsaw, Poland

Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology

🇵🇱

Warszawa, Poland

Pratia Onkologia Katowice

🇵🇱

Katowice, Śląskie, Poland

Institut català d'oncologia-hospital germans trias i pujol

🇪🇸

Badalona, Barcelona, Spain

Hospital Vall Hebron

🇪🇸

Barcelona, Spain

Institut Catala D'oncolocia

🇪🇸

Barcelona, Spain

Hospital Universitario La Paz

🇪🇸

Madrid, Spain

Hospital Virgen del Rocío

🇪🇸

Seville, Spain

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy